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Objective: To evaluate the cost-utility of adding tiotropium to usual care versus usual care
alone for patients with moderate to very severe chronic obstructive pulmonary disease (COPD)
in the UK and Belgium.
Methods: A four-state Markov model was developed with three disease severity states
(moderate, severe, very severe) and death. Severity was based on post-bronchodilator FEV1
and transitions were based on outcomes of the Understanding Potential Long Term Impacts
on Function with Tiotropium (UPLIFT) trial. Utilities were derived from EQ-5D scores for
a subset of UPLIFT patients. UK costs were evaluated separately for England (E), and for Scot-
land, Wales and Northern Ireland (SWNI). Belgian (B) costs were obtained from local sources.
Uncertainty was assessed by deterministic and probabilistic sensitivity analysis (PSA).
Results: Adding tiotropium to usual care resulted in an incremental cost per patient of V969
(B), £796 (E), and £812 (SWNI), and incremental QALYs of 0.052 (B), and 0.051 (E, SWNI).
The four-year incremental cost-effectiveness ratios (ICER) were V18,617 (B), £15,567 (E)
and £15,890 (SWNI) per QALY. Probability of tiotropium being cost-effective at £30,000
(V50,000) per QALY gained was greater than 60%.
Conclusions: At willingness to pay thresholds of £(V) 30,000 per QALY gained, adding tiotro-
pium to usual care is cost-effective.
ª 2012 Elsevier Ltd. All rights reserved.1582433650.
onhealth.com (R. Hettle).
2 Elsevier Ltd. All rights reserved.
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UPLIFT trial within a decision analytical model. Both costsTable 1 Baseline characteristics of patients enrolled in
UPLIFT.10
Characteristic Tiotropium
(N Z 2986)
Placebo
(N Z 3006)
Age (yr) 64.5  8.4 64.5  8.5
Male sex (%) 75.4 73.9
Duration of COPD (yr) 9.9  7.6 9.7  7.4
Current smoker (%) 29.3 29.9
Any respiratory
medication (%)
93.4 93.1
After Bronchodilation
FEV (% of predicted value)
47.7  12.7 47.4  12.6
GOLD stage II/III/IV (%) 46/44/8 45/44/9
Source Ref.10An estimated 1.6%e18.9% of the UK population1,2; and
between 5.5% (aged 55 years) and 9.5% (aged 75 years) of
the Belgian population have Chronic Obstructive Pulmonary
Disease (COPD).3 The management of COPD, as recom-
mended by the Global initiative for Chronic Obstructive
Lung Diseases (GOLD), includes the use of short- and long-
acting inhaled bronchodilators.4 In Belgium and the UK,
short-acting inhaled bronchodilators are recommended as
initial treatment for COPD, followed by long-acting bron-
chodilators in patients whose symptoms persist despite
short-acting treatment.5 Of the available long-acting
treatments, tiotropium (Spiriva) is the only once-daily
anticholinergic available for patients with moderate-to-
very severe COPD in UK and Belgium. In comparison to
placebo and short-acting anticholinergics (ipratropium),
tiotropium was found to consistently reduce the risk of
exacerbation and hospitalisation versus placebo and ipra-
tropium.6 Consistent and repeated treatment with long-
acting bronchodilators is considered both more effective
and more convenient than treatment with short-acting
bronchodilators.4
Several published economic evaluations have shown that
treatment with tiotropium leads to lower hospital costs and
better health outcomes compared to monotherapies,
resulting in cost-savings or cost-effectiveness favouring
tiotropium.7 In a recent systematic review, Mauskopf and
colleagues identified five model based economic evalua-
tions assessing the cost-effectiveness of tiotropium over 1-
year (NZ 3) and 5-year time horizons (NZ 2).7 All of these
studies modelled effect based on data from short-term
clinical trials. The 5-year models relied on the extrapola-
tion of data beyond the then available trial treatment
periods.8,9 The studies identified in this review demon-
strated that tiotropium provides better health outcomes
than standard monotherapies for a cost that represents
value for money. In some cases, tiotropium produced cost-
savings and was therefore the dominant product. More
importantly, the review highlighted the absence of studies
evaluating the costs and benefits of adding tiotropium to
other therapies (or usual care) and studies that evaluate
the long-term cost-effectiveness of tiotropium without
extrapolation of short-term trial data.7
Recently, the Understanding Potential Long-term
Impacts on Function with Tiotropium (UPLIFT) trial was
published, reporting comparative data on the clinical
benefits and safety of adding tiotropium to usual care.10
Over a four-year, randomised, double-blind controlled
treatment period, UPLIFT demonstrated that adding tio-
tropium to usual care (including respiratory medications
such as inhaled long-acting beta-agonists, inhaled cortico-
steroids and theophyllines, but excluding inhaled anticho-
linergics) increased patient quality of life, delayed the time
to first exacerbation and decreased the total number of
exacerbations.10 With access to this trial data, comes the
ability to evaluate the incremental cost and benefits of
adding tiotropium to usual care, and the ability to evaluate
long-term effects without extrapolation.
The aim of this study was therefore to assess the cost-
utility of adding tiotropium to usual care in patients withCOPD by applying the long-term individual data from the
and quality adjusted life years (QALY) were estimated over
the four year time horizon of the trial.10Methods
Overview
A cohort-based Markov model was developed based on the
outcomes of patients enrolled in UPLIFT.10 Results were
considered from the health care payer perspectives of
Belgium and the UK, with the UK consisting of two groupings
England, and Scotland, Wales and Northern Ireland (SWNI).
Both perspectives followed local guidelines on estimating
cost-effectiveness. In the UK, the National Health Service
(NHS) is responsible for health care provision, with other
health-related social and community care provided through
the Personal Social Services (PSS). Both organisations are
funded through national taxation, and in some cases, sup-
ported by nominal patient contributions through fixed
pharmaceutical prescription fees. In Belgium, national
health insurance is provided by the Institut National
d’Assurance Maladie-Invalidite (INAMI) and the Federal
Public Service Public Health (FPS Public Health). Both
federal institutions are responsible for the organisation,
financing and regulation of social security and public
healthcare provision. In Belgium patients pay on average
25% of healthcare expenditures out-of-pocket.
For the UK setting, the model simulated the total cost
borne by the NHS and PSS, including direct medical costs
such as usual care treatment and costs for hospitalisation.
Out of pocket expenses and indirect costs such as lost
productivity were excluded. For the Belgian analysis, the
model simulated costs as borne by INAMI, FPS Public Health
and patient out-of pocket expenses.11 Indirect costs were
excluded from the Belgian analysis.
For both the UK and Belgian simulations, costs and
health outcomes were evaluated over a four-year time
horizon, matching the UPLIFT trial study period.10 Table 1
summarises the baseline characteristics of patients
enrolled in the UPLIFT trial. The structure of the model
remained the same for both simulations. Resource
1724 R. Hettle et al.consumption, unit costs and utility weights differed
between the UK and Belgian simulations reflecting local
practices, costings and the health preferences from each
country as captured by utility tariffs. All other inputs
including the progression of disease and exacerbation rates
were assumed the same.
The outcomes of our study included the total cost of
COPD care, cumulative QALY, and the expected number of
exacerbations in patients receiving tiotropium versus usual
care alone. Cost-effectiveness was determined by the
incremental cost-effectiveness ratio (ICER), measured in
terms of cost per QALY gained and the cost per exacerba-
tion avoided.
Costs reported for UK were in pounds Stirling (year e
2011), with Belgian costs reported in Euros (2011). Both costs
and benefits were discounted at a rate of 3.5% per annum in
the UK and 3% and 1.5% per annum in Belgium,11 respec-
tively. Univariate and probabilistic sensitivity analyses were
conducted to assess the robustness of model outcomes.Figure 1 Markov model state diagram. Note: X, Y, Z are
determined by exacerbation rates specific to each disease state.Model structure
Cost-utility of adding tiotropium to usual care versus usual
care alone in the management of COPD was evaluated using
a Markov model. The placebo arm of the UPLIFT trial re-
flected usual care as all respiratory medications, except
other inhaled anticholinergic drugs, were permitted during
the trial.
The Markov model was based on a previously published
COPD model which estimated the cost-effectiveness of
tiotropium compared to ipratropium and salmeterol over
one-year.8,9,12e16 This model was adapted by extending the
time-horizon from one to four years, and including death as
an additional Markov state.
The model comprised four mutually exclusive disease
states, representing three levels of disease severity and
death. Each level of disease severity was defined according
to the international GOLD guidelines and in accordance
with the recent NICE COPD guidelines, evaluated by FEV1
post-bronchodilation, the standard diagnostic tool for
COPD.4,5,17 Disease states in the model represent moderate
(50e80% of predicted FEV1), severe (30e49% of predicted
FEV1) and very severe COPD (<30% of predicted FEV1),
4 and
death (Fig. 1).
The length of each Markov cycle was set to one month.
This cycle length was selected to fully capture the resource
use and quality of life associated with disease progression
and exacerbation events.
During each cycle, patients could improve in disease
severity, remain in the same health state, experience dete-
rioration in lung function or die (COPD adjusted all-cause
mortality). The model allowed for the possibility of progres-
sion to a less severe disability as patients experienced
increased bronchodilation following treatment. Discontinu-
ation of treatment was modelled based on the withdrawal
rates observed in the UPLIFT trial. Within any given cycle,
patients may also experience exacerbations that may ormay
not require hospitalisation. Patients who are hospitalised
during an exacerbation event incurred greater costs and
reduced quality of life compared to those who do not require
hospitalisation. In both cases, an exacerbation event wasdefined as the onset or increase in more than one respiratory
symptomlasting threedaysormore.The initialdistributionof
COPDpatients prior to cycle 1was 46%moderate, 45% severe,
and 9% very severe.10
Inputs common to both simulations
Clinical inputs
To model disease progression in the COPD cohort, separate
transition matrices for first and subsequent cycles for both
intervention and usual care arms of the UPLIFT trial were
evaluated.10 In doing so, increased variations in treatment
effect observed during the first 30 days of treatment were
appropriately accounted for. Following the initial 30 day
time period, the UPLIFT trial found no significant differ-
ence in the rate of decline in mean FEV1 between treated
and control patients, although the improvement in mean
FEV1 observed during the first 30 days of the trial was
maintained at all time points.10 As such, the main effect of
treatment was modelled during the initial 30 days with the
cumulative effect of treatment retained for all subsequent
cycles. To estimate the transition matrices, patient level
data from the UPLIFT trial was analysed using the Multi-
State Markov package in R.18e20 Details of the data
screening and code for the analysis can be found in the
supplementary literature.
The exacerbation rates were derived from observed
exacerbations in the UPLIFT trial,10 defined by disease
state and exacerbation severity (Table 2). As observed in
the trial, patients with a more severe deterioration in lung
function had higher exacerbation rates.
Quality of life
Utility weights were assigned independently to each
disease state, and to each exacerbation event. Utility
weights by disease state were derived from a representa-
tive subset of patients enrolled in UPLIFT using the Euro-
Qol Five-Dimension Questionnaire (EQ-5D).21,22 Domain
scores for each patient were mapped to utility weights,
using local tariffs.11,23,24 In both simulations, the utility
weight for the death state was zero.
Disutility of hospitalised and non-hospitalised exacer-
bations were based on the patient’s disease state, which
was reduced by 15% for non-hospitalised exacerbation
events and 50% for hospitalised exacerbation events.15
Table 2 Exacerbation rates per patient per month (UPLIFT trial).
Treatment Exacerbation Moderate mean (lower
95% CI, upper 95% CI)
Severe mean (lower
95% CI, upper 95% CI)
Very severe mean (lower
95% CI, upper 95% CI)
Tiotropium plus
usual care
Severe exacerbation 0.007 (0.006, 0.008) 0.017 (0.015, 0.018) 0.029 (0.023, 0.037)
Non-severe exacerbation 0.040 (0.038, 0.043) 0.054 (0.052, 0.048) 0.058 (0.053, 0.040)
Usual care alone Severe exacerbation 0.008 (0.007, 0.010) 0.018 (0.015, 0.019) 0.029 (0.023, 0.038)
Non-severe exacerbation 0.050 (0.048, 0.053) 0.063 (0.061, 0.067) 0.067 (0.060, 0.072)
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Costs were attributed to each exacerbation event and for
each patient receiving maintenance treatment. In each
cycle, a monthly cost was attributed to each patient in
a given disease state, independent of treatment assign-
ment. Severe exacerbation costs included inpatient and
post-discharge care and non-severe exacerbation costs
included all non-hospitalised care. Different costs were
applied in the Belgian, England, and SWNI simulations,
reflecting differences in practice, healthcare costs, and
healthcare cost structures across these countries.
Inputs that differ between simulations
United Kingdom inputs
Quality of life
For the UK simulations, EQ-5D domain scores were mapped
to utilities using the UK tariff,22,24 reflecting the social
preferences of patients in UK. Utility weights were assigned
as 0.787 (95% CI, 0.771e0.802) for moderate, 0.750 (95% CI,
0.731e0.768) for severe and 0.647 (95% CI, 0.598e0.695)
for very severe COPD.
Costs
Resource utilisation for each disease severity state was
estimated using a Delphi panel. The panel comprised four
General Practitioners and four secondary care consultants
from across the UK. Unit costs, obtained from various
sources including the Personal Social Services Research Unit
(PSSRU) and the NHS National Tariff 2009/2010, were
applied (Table 3). The costs associated with exacerbations
were calculated separately for England, and for SWNI, to
account for variability in the use of national tariffs.
For England, costs were estimated using Health Related
Group (HRG) codes, with the proportion of patients within
each HRG and the proportion with long stay defined by the
expert panel. For SWNI, costs were estimated from the
proportion and resource use of hospitalisations, obtained
from the expert panel. The costs of hospitalised exacer-
bations in England were estimated at £3726 per event, and
£3329 in Scotland, Wales and Northern Ireland. The cost ofTable 3 Monthly cost of managing COPD in the UK by
health state and type of cost (excluding tiotropium) [2011].
Moderate Severe Very severe
Prescription costs £24.40 £29.73 £40.20
Non-prescription costs £15.10 £53.15 £96.67
Total maintenance
cost per cycle
£39.50 £82.88 £136.87non-hospitalised exacerbations was £118 per event in both
settings. Tiotropium cost £32.13 per month.25
In all cases, uncertainty surrounding cost estimates were
included within the full probabilistic sensitivity analysis.
Belgium inputs
Quality of life
For the Belgian simulation, EQ-5D domain scores were map-
ped to utility weights using the Flemish tariff,11,22,23 reflect-
ing the social preferences of patients in Belgium. Health
utility weights by state were 0.749 (95% CI, 0.734e0.764) for
moderate, 0.710 (95% CI, 0.692e0.728) for severe, and 0.604
(95% CI, 0.562e0.647) for very severe COPD.
Costs
Resource utilisation was captured from a primary analysis
of a longitudinal database of COPD patients in Belgium,
supplemented by two prospective surveys of General
Practitioners (GPs). The surveys were used as both explor-
atory assessments of prescribing patterns (first survey) and
to fill data gaps from the retrospective database analysis
(second survey). The purpose of this analysis was to esti-
mate the annual resource utilisation for a sample of
patients with moderate, severe and very severe COPD.
Information was collected from patients who met the
following inclusion criteria: diagnosed for at least one year
with moderate, severe or very severe COPD as per the GOLD
guidelines4 and having been treated by the representative
GP for at least one year.
The first survey was distributed to a sample of 15 Belgian
GPs selected from a Belgian advisory panel (June, 2010). Of
the 15 contacted, 10 GPs participated. Within the survey,
each GP was asked to report medical information on
a representative sample of six anonymous COPD patients
meeting the inclusion criteria described previously. The GPs
were instructed to select two patients for each of the three
GOLD severity stages used in the model and to report
information on maintenance treatment and treatment for
severe and non-severe exacerbations.
Further data were obtained from a local longitudinal
database specifying the treatment and follow-up of Belgian
COPD patients in primary care. To fill data gaps, a follow-up
(second) survey was conducted (online), requesting the
same information as the original exploratory (first) survey.
Overall, 55 GPs agreed to participate, representing
approximately 350 patients in Belgium with moderate,
severe and very severe COPD. Additional detail on the
surveys can be found in the Supplementary Appendix.
Unit costs were obtained from INAMI nomenclature
(2011); IMS sales data (2010); Technical cell for hospital
data, National Medical Diagnosis Database (www.tct.fgov.
Table 4 Monthly cost of managing COPD in the Belgium by
health state and type of cost (excluding tiotropium) [2011].
Moderate Severe Very severe
Prescription costs V60 V87 V209
Non-prescription costs V36 V87 V168
Total maintenance
cost per cyclea
V97 V173 V376
a Discrepancies in final values due to rounding.
1726 R. Hettle et al.be); a local sickness fund and the literature.26 Costs were
inflated to 2011 prices using the national health index (www.
statbel.fgov.be). Table 4 summarises the monthly mainte-
nance cost by prescription and by disease state in patients
receiving usual care. Prescription costs included all phar-
macotherapies, and non-prescription costs included primary
care, diagnostic tests and vaccinations. The monthly cost of
tiotropium (not included in Table 4) was V51.
The cost of a hospitalised exacerbation was V7590 and
included both hospital and post discharge costs. The cost of
a non-hospitalised exacerbation was V231 and included
pharmacotherapy and other non-hospitalised care costs.
Validity of the model
Validation of the predictive quality of the model was
assessed by considering the difference in modelled
outcomes to those observed in the UPLIFT trial.
Base case analysis
The base case analysis evaluated the experience of 10,000
patients over four years. For the UK base case, results for
England, and for SWNI, are reported separately. Both UK
and Belgian results were reported on a per patient basis.
Sensitivity analysis
Uncertainty in the model was assessed using deterministic
and probabilistic sensitivity analyses (PSA) in both UK and
Belgian simulations.
For the PSA, distributions were assigned for each key
input in both UK and Belgian simulations. Uncertainties inTable 5 Parameters and related distributions defined for the P
Parameter Probability dis
Disability progression transition matrices Dirichlet
Rate of exacerbation Gamma
Health utility Log-normal
Healthcare utilisation e proportion of patients
requiring each healthcare utilisations
Beta
Healthcare utilisation e direct
resource utilisation
Gamma/Norminputs were propagated through the model using second
order Monte Carlo simulations. For each Monte Carlo
simulation, each input was randomly and simultaneously
sampled from its respective distribution before results were
captured, and the process repeated. 10,000 iterations were
performed, with the measurement of uncertainty reported
in terms of cost-effectiveness planes and cost-effectiveness
acceptability curves, evaluating the probability of cost-
effectiveness by a range of willingness to pay thresholds.
The results of this analysis represent the joint conse-
quences of uncertainty in all key inputs, identified based on
the results of the DSA, where one-way variability was
judged to produce sensitivity in model outcomes (Table 5).
UK deterministic sensitivity analyses
The UK DSA assumed a 25% interval across all model
parameters. The purpose of this analysis was to determine
the sensitivity of results to variability in model parameters
and to evaluate the results of the model for pre-specified
patient sub-groups of: moderate patients only; severe
patients only; and very severe patients only.
Belgian deterministic sensitivity analyses
The Belgian DSA considered variations in key input param-
eters expected to have a significant influence on the
outcome of the model, and for cases where alternative
data inputs were found. This includes the initial distribution
of patients by disease state, obtained from an observa-
tional data set in Belgium (data on file, 2007), percentage
of patients receiving influenza vaccination (data on file,
2010) and the percentage of patients receiving daily oxygen
therapy (data on file, 2007). Further detail can be found
Table 9.
Results
UK
Base case
The results of the UK base case analyses indicate that
patients on tiotropium experience better health related
quality of life (0.051 incremental QALY), as measured by
discounted cumulative QALYs, in return for a higher
cumulative discounted cost (£812 [SWNI] and £796 [E]
incremental cost) (Table 6). The resulting incremental cost-SA.
tribution Source of uncertainty
Frequency of patient transition as observed
in UPLIFT data e data on file
See Table 2
Standard errors based on confidence intervals
from original source22
Standard errors based on responses from
expert panel (UK) and observational data
(Belgium) e data on file
al/Uniform Standard errors based on responses from
expert panel (UK) and observational
data (Belgium) e data on file
Table 6 Results of the deterministic analysis (UK) (base case, per patient over four years; discounted).
Intervention
(drug)
Costs Total
costs
Total
QALY
Incremental
exacerbation
(maintenance) cost
Incremental
total cost
Incremental
QALY
ICER
Maintenance
costs
Exacerbation
costs
England
Tiotropium £3937 £2538 £6475 2.645 £206 (£1001) £796 0.051 £15,567/QALY
Usual care £2935 £2744 £5679 2.594
SWNI
Tiotropium £3937 £2295 £6231 2.645 £189 (£1001) £812 0.051 £15,890/QALY
Usual care £2935 £2484 £5419 2.594
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QALY gained for England, and SWNI, respectively.
Deterministic sensitivity analysis
Overall, the results of the DSA found tiotropium to be cost-
effective across the sensitivity analyses, with ICERs where
parameters were tested varying from £12,000 to £30,000 per
QALY gained (Table 7). The largest change in ICER
was observed where the patient population was varied, with
tiotropium most cost-effective in the less severe patients.
Probabilistic
For both England and SWNI, the probability of cost-
effectiveness at a willingness to pay threshold of £30,000
was over 60%. Overall, in 87% of iterations, tiotropium was
more effective, and in 31% (England) and 29% (SWNI) of
iterations, tiotropium was more effective and cost-saving
(dominant). The cost-effectiveness acceptability curves areTable 7 Results of the DSA (UK).
England
ICER
Base case £15,567
Utility scores moderate, severe
and very severe COPD: 0.750, 0.750, 0.647
£18,449
Utility scores moderate, severe and
very severe COPD: 0.787, 0.647, 0.647
£12,478
Relative decrease in utility for
non-hospitalised exacerbation of 50%
£13,110
Relative decrease in utility for non-hospitalised
exacerbation of 0%
£16,926
Relative decrease in utility for hospitalised
exacerbation of 75%
£15,366
Relative decrease in utility for hospitalised
exacerbation of 25%
£15,773
Increase in the cost of usual care by 25% £15,553
Decrease in the cost of usual care by 25% £15,581
Discounting outcomes by 6% £16,564
Discounting outcomes by 0% £14,290
Discounting costs by 6% £14,888
Discounting costs by 0% £16,562
Moderate only patients £12,109
Severe only patients £18,996
Very severe only patients £29,210shown in Fig. 4, and the cost-effectiveness planes in Figs. 2
and 3.
Belgian simulation
Base case
As with the UK analysis, the results of the Belgian base case
analysis indicate that patients on tiotropium experience
better health related quality of life (0.052 incremental
QALY) in return for a higher cumulative discounted cost
(V969 incremental cost). The resulting ICER was V18,617
per QALY gained (Table 8).
Deterministic
Overall, the results of the DSA found tiotropium to be cost-
effective across the sensitivity analyses, with ICERs varying
between V15,500 and V23,300 per QALY in Belgium. Vari-
ations in utility scores had the largest impact on outcomes,SWNI
Relative change
versus base case
ICER Relative change
versus base case
£15,890
18.5% £18,832 18.5%
19.8% £12,738 19.8%
15.8% £13,383 15.8%
8.7% £17,278 8.7%
1.3% £15,686 1.3%
1.3% £16,101 1.3%
0.1% £15,876 0.1%
0.1% £15,904 0.1%
6.4% £16,908 6.4%
8.2% £14,587 8.2%
4.4% £15,196 4.4%
6.4% £16,910 6.4%
22.2% £12,392 22.0%
22.0% £19,437 22.3%
87.6% £29,210 83.8%
Figure 2 Cost-effectiveness plane for England.
1728 R. Hettle et al.accounting for both the maximum and minimum range of
ICERs reported (Table 9).
Probabilistic
For Belgium, the probability of cost-effectiveness at
willingness to pay thresholds of V20,000 and V50,000 perFigure 3 Cost-effectiveQALY gained was 50% and 62% respectively. As with the UK
simulation, 88% of iterations showed favourable outcomes
for tiotropium and 35% of iterations showed dominance
in favour of tiotropium. The cost-effectiveness
acceptability curves and planes are shown in Figs. 5
and 6.ness plane for SWNI.
Figure 4 Cost-effectiveness acceptability curve for England and SWNI.
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In UPLIFT, the addition of tiotropium to usual care
improved lung function, quality of life and reduced exac-
erbations when compared to usual care alone over a four-
year period.10 In the present study, we demonstrated that
the addition of tiotropium to usual care is cost-effective
from the payer perspective in Belgium and the UK. In
both the UK and Belgium, the additional cost of adding
tiotropium to usual care was partially offset by savings in
hospitalisation costs. In all settings, adding tiotropium to
usual care produced a gain in QALYs, resulting in an ICER
below the conservative willingness to pay thresholds of
V20,000, and £20,000 per QALY gained.
Within the UK, the difference in results between England
and SWNI was minimal, driven exclusively by a slightly
higher cost of hospitalisation for severe exacerbations in
England. Tiotropium is estimated to have an ICER of £15,380
in England, with a probability of at least 60% of falling
below NICE’s £30,000 per QALY threshold, above which new
technologies are unlikely to be recommended. In SWNI, we
estimate an ICER of £15,790.
In Belgium, in the absence of an official willingness to
pay threshold from which treatments can be consideredTable 8 Results of the deterministic analysis (Belgium) (base c
Intervention
(Drug)
Payer costs Total
costs
Total
QALY
Inc
exa
(ma
Maintenance
costs
Exacerbation
costs
Belgium
Tiotropium V8411 V4802 V13,213 2.609 V
Usual care V6892 V5352 V12,244 2.557cost-effective, tiotropium was appraised against a willing-
ness to pay threshold of between V20,000 and V30,000 per
QALY gained, assuming equivalence without currency
adjustment to the guide threshold applied by NICE in the
UK. Previous cost per QALY thresholds have included values
up to V50,000 per QALY, determined by adjusting the
£30,000 threshold used by NICE to Euros. In both cases,
tiotropium was considered cost-effective, with a determin-
istic base case ICER of V18,617, with at least 62% of iter-
ations cost-effective at a willingness to pay threshold of
V50,000.
Within this study, societal costs such as absenteeism
from work and lost productivity from premature mortality
were not considered. The broader societal perspective is
not routinely considered in the UK or Belgium, and there-
fore was not considered relevant to this analysis. Despite
this, the results presented support the hypothesis that
tiotropium is cost-effective under a societal perspective, as
the benefits in reducing the time to and rate of exacerba-
tion events whist receiving tiotropium would lead to fewer
days absent from work. This would reduce the total incre-
mental societal cost of tiotropium. Therefore, as tio-
tropium is cost-effective under a narrower, payer
perspective, it is likely that tiotropium will be cost-ase, per patient over four years; discounted).
remental
cerbation
nagement) cost
Incremental
total cost
Incremental
QALY
ICER
550 (V1519) V969 0.052 18,617V/QALY
Table 9 Results of the one-way and two-way sensitivity analyses in Belgium.
Belgium
ICER Relative change
versus base case
Base case V18,617
Utility scores moderate, severe and very severe COPD: 0.599, 0.568, 0.483 V23,300 25.15%
Utility scores moderate, severe and very severe COPD: 0.899, 0.852, 0.725 V15,511 16.68%
Relative decrease in utility for hospitalised exacerbation of 75% and
non-hospitalised exacerbation of 22.5%
V17,693 4.96%
Relative decrease in utility for hospitalised exacerbation of 25% and
non-hospitalised exacerbation of 7.5%
V19,642 5.51%
Initial distribution of patients by disease state; moderate (49%),
severe (36%) and very severe (15%) COPD
V18,916 1.61%
Initial distribution of patients by disease state; moderate (54%),
severe (36%) and very severe (10%) COPD
V17,975 3.45%
Percentage of patients receiving influenza vaccination by disease state;
moderate (95%), severe (95%) and very severe (95%) COPD
V18,620 0.02%
Percentage of patients receiving pneumococcal vaccination by disease state;
moderate (45%), severe (45%) and very severe (55%) COPD
V18,622 0.03%
Percentage of patients receiving daily oxygen therapy by disease state;
moderate (0.8%), severe (3.6%) and very severe (19.5%) COPD
V20,093 7.93%
Proportion of patients transported by ambulance (20%) V18,790 0.93%
Proportion of patients transported by ambulance (80%) V18,443 0.93%
Moderate only patients V13,821 26%
Severe only patients V22,945 23%
Very severe only patients V38,932 109%
1730 R. Hettle et al.effective under a societal perspective, and that the current
analysis can be considered the upper limit for a societal
analysis.
The key strengths for this study include a comprehensive
model structure reflecting the course of the disease andFigure 5 Cost-effectivenmodel input parameters that were derived from individual
patient data from UPLIFT. Furthermore, outcomes were
calculated over a four-year period without the need for
extrapolation, which otherwise requires broad assumptions
on time dependency in model parameters.ess plane for Belgium.
Figure 6 Cost-effectiveness acceptability curve (cost per QALY) for tiotropium versus usual care for Belgium.
Tiotropium cost-utility analysis 1731By undertaking an extensive sensitivity analysis of model
assumptions, we sought to evaluate the sensitivity of the
model to alternative assumptions and test the robustness of
the results. In general, outcomes were insensitive to
assumptions surrounding health utilities, discounting of
costs and utilities, and cost of disease management, with
ICERs consistently falling within accepted willingness to pay
thresholds, thus highlighting the robustness of model
outcomes to alternative assumptions.
Results from the sub-group analyses by disease severity
indicated that the most cost-effective of these subgroups
for prescribing tiotropium in addition to usual care were
patients with moderate disease severity. Patients with
moderate COPD are treated for longer and thus experience
an increased health benefit over those with more severe
disease.
All adaptations to the model were limited to efficacy,
cost and utility parameters, allowing the accurate model-
ling of the outcomes of UPLIFT. As such, the structure
employed within our model has been extensively validated
and peer-reviewed elsewhere.15 This includes the use of
a Markovian health state structure, which is subject to the
Markov assumption, such that a cohort’s future progression
is dependent only on their current state of health. Whilst
this assumption may not hold true when estimating the
prognosis of an individual patient, it may be more realistic
when considering the effect of disease progression on
a cohort of patients. Although, this approach has been
accepted and applied elsewhere,15 the results of this study
should be viewed in light of this limitation.
A potential limitation in this model structure suggested
by NICE in the UK and the Health Care Knowledge Centre
(KCE) in Belgium concerns the application of treatment
effect to both disease progression and rates of exacerba-
tion. This limitation centres around uncertainty over theeffect of tiotropium on disease progression.5 In the current
model, the effect of treatment, in terms of both disease
progression and exacerbation reduction, was based directly
on the experience of patients enrolled in the UPLIFT trial,
which reported patients who received tiotropium as
exhibiting significant improvements in mean FEV1 scores in
the first 30-days post randomisation.10 Furthermore, the
model validation demonstrated that the model replicated
the clinical trial findings, thus was very well calibrated.
Another limitation in the model that warrants discussion
is the application of resource data from a Delphi panel in
the UK, and uncertainty relating to the quality of life
impact of exacerbations (based on assumptions in previous
evaluations). The limitations of applying data from the UK
Delphi panel have been addressed elsewhere in the litera-
ture.12 Overall, consistency between healthcare resource
group costs for England, and the costs estimated from the
Delphi panel for the rest of the UK, was high. This consis-
tency validates the results of the Delphi panel, given the
robust nature of the HRG costings.
Using clinical data from randomised clinical trials for
cost-effectiveness modelling to inform health care decision
makers always brings up the question of external validity.
As with all cost-effectiveness modelling studies, the data
used to populate the model will determine the settings to
which the results of the analysis may apply. In this analysis,
data from UPLIFT is applied to evaluate the effectiveness of
tiotropium and placebo.10 The UPLIFT trial population
might differ from the overall COPD population as certain
inclusion and exclusion criteria were applied for study
enrolment (for example, inclusion criteria included an age
of 40 years or more and a smoking history of at least 10-
pack years) and as the selection of investigators may not
be representative of the health care providers treating
COPD patients in the country settings investigated, because
1732 R. Hettle et al.patients were largely enrolled in hospital-based centres.10
Therefore, the results of our cost-effectiveness analysis
are directly relevant to this population, and cannot easily
be generalised to other COPD populations. Future studies
on population or general practice based patient groups are
required to draw final conclusions.
In relation to quality of life and exacerbations, there
currently exists a lack of literature reporting quality of life
during exacerbations, and as a result, similar assumptions
have been applied in previous cost-effectiveness studies in
COPD.9,14,16,27,28 Further research to quantify the impact of
exacerbations on health utility is needed. In varying this
assumption, sensitivity analyses showed little variability in
the ICER, indicating that outcomes were insensitive to the
choice, or assumption, in the magnitude of utility decre-
ment per exacerbation.
Characteristics of the model include its comparability
with the clinical endpoints of UPLIFT, and the inclusion of
utility values derived from the preferences of the UPLIFT
trial population. In comparing the predictive quality of the
model, it was found that the relative risk of exacerbations
between tiotropium and usual care, as modelled in the
current analysis (0.86), compared well to the outcome re-
ported in the trial (0.86).10
It is recognised that UPLIFT included patients on a high
level of background treatment for COPD; 60% of patients
received long-acting beta-agonists and 62% received inhaled
corticosteroids.10 Thus, this analysis answered the decision
problemwhether the addition of tiotropium to intense ‘usual’
therapy still confers ‘good value for money’. Previous studies
have demonstrated tiotropium to be cost-effective if used
instead of other treatments,7 but the hurdle to achieve
acceptable ICERs in an ‘add-on’ scenario is considerably
higher as it can be expected that incremental clinical effects
are diminishing as treatment is intensified.
Conclusion
In this study,we consider the cost-effectiveness of tiotropium
in comparison to usual care over a 4-year time horizon and
demonstrate that tiotropium remains a cost-effective ther-
apeutic strategy. Thus, despite theadditional acquisition cost
of tiotropium, the health benefits and cost-savings achieved
primarily through reduced exacerbations, offer the potential
to reduce theburdenofCOPD fromthe perspectiveof theNHS
in the UK, and of the healthcare payer in Belgium.
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